TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01756183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 + Paclitaxel Chemotherapy
Description: Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1
Study: NCT00663754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder prevention program
Description: Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational brochure
Description: Participants will receive a mailed educational brochure about a healthy body image only.
Study: NCT03522220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D navigation video game intervention
Description: Participants intensively train with a video game (Super Mario DS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video game intervention without 3D navigation
Description: Participants train with a video game (Super Mario Bros)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No 3D navigation
Description: Participants read on a kindle device (control group)
Study: NCT00544791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 5 mg, oral, daily dose for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like melatonin tablets
Study: NCT02830321

Intervention type: OTHER
Intervention: helicopacter pylori stool antigen test (CER TEST BIOTEC)
Description: Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum

Intervention type: OTHER
Intervention: helicopacter pylori stool antigen test (CER TEST BIOTEC)
Description: Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
Study: NCT03700489

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
Study: NCT03487497

Intervention type: PROCEDURE
Intervention: Lateral column lengthening osteotomy
Description: Lengthening osteotomy of the lateral column of the foot
Study: NCT00612560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 25 g per day ground

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 25 g per day ground

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill 1 per day
Study: NCT03579043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritive Sweetener
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Nutritive Sweetener
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
Study: NCT00580502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND® Adjustable Gastric Band (LAGB®)
Description: Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
Study: NCT00713037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoromisonidazole-PET/CT
Description: 2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
Study: NCT00430586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A, free of complexing proteins
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
Study: NCT03965195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Influenza Vaccine
Description: Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Quadrivalent Influenza Vaccine
Description: Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
Study: NCT01980030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT02920671

Intervention type: OTHER
Intervention: Tracer-enhanced oral glucose tolerance test (OGTT*)
Description: Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.

Intervention type: OTHER
Intervention: Tracer-enhanced oral glucose tolerance test (OGTT*)
Description: Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.

Intervention type: OTHER
Intervention: Tracer-enhanced oral glucose tolerance test (OGTT*)
Description: Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.

Intervention type: OTHER
Intervention: Muscle MRI
Description: Non-invasive muscle MRI will be performed to evaluated metabolic capacity.

Intervention type: OTHER
Intervention: Muscle MRI
Description: Non-invasive muscle MRI will be performed to evaluated metabolic capacity.

Intervention type: OTHER
Intervention: Muscle MRI
Description: Non-invasive muscle MRI will be performed to evaluated metabolic capacity.

Intervention type: OTHER
Intervention: Dual energy x-ray absorptiometry (DXA)
Description: DXA will be performed to evaluate body composition.

Intervention type: OTHER
Intervention: Dual energy x-ray absorptiometry (DXA)
Description: DXA will be performed to evaluate body composition.

Intervention type: OTHER
Intervention: Dual energy x-ray absorptiometry (DXA)
Description: DXA will be performed to evaluate body composition.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be used to evaluate participants' health and habits.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be used to evaluate participants' health and habits.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be used to evaluate participants' health and habits.
Study: NCT00590616

Intervention type: PROCEDURE
Intervention: transthoracic examination
Description: observational transthoracic examination
Study: NCT03689465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
Study: NCT00518167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle counselling
Description: Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week
Study: NCT00634933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
Study: NCT03689465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin A (CsA)
Description: In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin A (CsA)
Description: In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)
Description: In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
Study: NCT00634933

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
Study: NCT02171195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
Study: NCT00634933

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
Study: NCT02171195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.
Study: NCT03846323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visiting policies: 24 hours a day, 7 days a week

Intervention type: OTHER
Group type: OTHER
Intervention: Restriction of visiting policies < 6 hours
Study: NCT00664729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Reduced calorie diet (400 kcal/day deficit)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction + Low-Intensity aerobic exercise
Description: 400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction plus High-intensity aerobic exercise
Description: 400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
Study: NCT03778281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyclopramide
Description: Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyclopramide
Description: Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Study: NCT00843128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted gait training (RAGT)
Description: 20 patients will be treated with RAGT, 12 sessions over three weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional walking training (CWT)
Description: The control group will be treated by CWT, 12 sessions in three weeks.
Study: NCT01349816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days
Study: NCT02171195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.
Study: NCT01444261

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fer-in-Sol
Description: Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No dietary supplements
Study: NCT03027024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of IOL: PhysIOL POD F GF
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study: NCT02939794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (normal saline, sodium chloride)
Study: NCT02756611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablets for oral administration
Study: NCT03399045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9-minute withdrawal
Description: Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute withdrawal
Description: Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
Study: NCT03092219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA Redensity
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study: NCT00790725

Intervention type: OTHER
Group type: OTHER
Intervention: Proportional Assist Ventilation
Description: Proportional Assist Ventilation will be used to ventilate the patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Support Ventilation
Description: Pressure Support ventilation will be used to ventilate the patients.
Study: NCT03579043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbonated Water
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
Study: NCT00487071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Study: NCT01645410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study: NCT02666443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control intervention (no dexamethasone)
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-neural Dexamethasone 1 mg
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone 1 mg
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%